PDCD1 and sarcoma: Since monotherapy with PD-1 or CTLA-4 inhibitors showed modest improvement in sarcoma patients’ survival, novel combinations with cytotoxic agents, anti-angiogenic agents, etc., are undergoing active investigation to induce consistent and durable responses (Pollack et al., 2018; Gamboa et al., 2020).